Cipla

Cipla ready to launch low-dose Efavirenz 400 mg

Studies found that the reduced dose of 400 mg Efavirenz was non-inferior to the standard dose of 600 mg Efavirenz dose

Cipla inks investment pact with FIL Capital Investment

No financial deals of the agreement were disclosed

Delhi HC tells govt not to take coercive steps against pharma cos

Petitions were filed by pharma companies and an association of medicine manufacturing firms challenging the government’s new drug pricing order that asked them to slash prices of 348 medicines The Delhi High Court has t

Cipla appoints Naina Lal Kidwai as Independent Director on its Board

She received the Padma Shri Award in 2007 from Government of India Cipla has announced the appointment of Naina Lal Kidwai as an independent director on its board effective November 6, 2015. Until recently Kidwai was Executiv

Cipla to sell entire stake in Biomab Holding for $25,775,000

Drug major Cipla has entered into an agreement to sell its entire stake in Biomab Holding to Biomab Brilliant Ltd for a consideration of USD 25,775,000 to focus on biological segment under its arm Cipla BioTec.

Cipla stake

Cipla to strengthen its focus on biotech

Divests its remaining stake in Hong Kong-based Biomab Holding to focus on global development under Cipla BioTec Cipla has entered into a definitive agreement to sell its entire 25 per cent stake in Biomab Holding Limited, Hon

Cipla’s Indore plant under US FDA scanner

As many as nine issues have been raised by the regulator under ‘Form 483’ regarding manufacturing practices in the plant Cipla’s Indore plant has come under the scanner of US health regulator for manufacturi

Cipla falls; traders cite FDA concerns over InvaGen plant

Cipla, India's fourth-largest drugmaker by sales, falls as much as 3 pct to 660 rupees.

Cipla stake

India battles big pharma over cough syrup abuse, reducing supplies

Regulators want to make it easier for law enforcement agencies to track cough syrup abuse in the country and bottles smuggled to neighbouring Bangladesh, where it was banned in the 1980s but is still sought by addicts.

cough syrup codeine

Cipla Medpro in agreement with Serum Institute India

To provide vaccines in South Africa

Cipla inks pact with Biopharma SPA to establish joint venture in Algeria

Drug major Cipla has inked a pact with Biopharma SPA for establishing a joint venture company in Algeria to manufacture and market respiratory products.

Cipla stake

Buy rating on Cipla; buys a shot in its arm: HSBC

Cipla acquires two generics businesses in the US: Cipla has announced it is acquiring two privately held generic pharma businesses, InvaGen and Exelan Pharma, in the US for a transaction value (TV) of $550m.

Prescription for growth: A booster dose for Cipla

Marking its second biggest acquisition in eight decades, Cipla last week announced the buyout of two US-based drug firms InvaGen Pharma and Exelan Pharma in a cash deal pegged at $550 million.

subhanu saxena cipla

Prescription for growth: A booster dose for Cipla

Marking its second biggest acquisition in eight decades, Cipla last week announced the buyout of two US-based drug firms InvaGen Pharma and Exelan Pharma in a cash deal pegged at $550 million.

Cipla stake

Cipla enhances US push with 2 buys for $550 mn

With a view to enhance its presence in the world's largest generics market, Cipla on Friday said it would acquire 100% of generic businesses of two pharmaceutical companies in the US for $550 million in a cash deal.

Cipla stake

Cipla shares gain on acquisition of 2 US generic firms for $550 million

Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals and Exelan Pharmaceuticals for a total of $550 million to be paid in cash.

sensex, nifty, bse, nse, stock market today

Stocks that are in focus today: Cipla, ONGC, Wipro and more

Cipla stocks will be in focus today as the the Indian generic drugmaker on Friday informed BSE that its UK arm, Cipla EU, has entered into definitive agreements to acquire two US-based companies InvaGen Pharmaceuticals Inc an

Godrej Properties share price, Sensex

Cipla to buy two US generics firms InvaGen Pharmaceuticals, Exelan Pharmaceuticals for $550 mn

Indian generic drugmaker Cipla on Friday informed the Bombay Stock Exchane that its UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals Inc and Exelan Pharmaceuti

Cipla stake

Cipla to acquire US-based InvaGen Pharmaceuticals and Exelan Pharmaceuticals

Signs agreements to acquire 100 per cent of generic businesses in the US for $550 million Cipla’s UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals and Ex

Cipla appoints Umang Vohra and Prabir Jha to its management team

Vohra will be the global chief financial and strategy officer and Jha will take over as global chief people officer Cipla has appointed Umang Vohra as global chief financial and strategy officer and Prabir Jha as global chief

Stocks in focus today: DLF, Tata Motors and more

Tata Motors' stocks will be in focus as the company on Tuesday said its August growth remained flat at 40,680 units compared to 40,883 vehicles in the same month last year.

Stocks in focus today - brexit worries

Cipla gains 3 per cent on strong revenue outlook

Shares of Cipla on Friday soared nearly 3 per cent in morning trade on bourses after the company said it expects 20 per cent growth in revenues in the current fiscal.

Cipla stake

Cipla urges government to support capital investment, R&D for pharma industry

Recommends creating a favourable tax regime to help growth of the pharma industry

Sensex companies’ Q1 profit grew by around 1% YoY

Net profit of the Sensex companies grew by around 1 per cent year-on-year (YoY) for the previous quarter ended June 2015.

sensex and nifty

Cipla announces Q1 FY15-16 unaudited consolidated financial results

Profit after tax grew by 120.9 per cent to Rs 651 crore, up from Rs 295 crore Cipla has announced its unaudited consolidated financial results for the quarter ended June 30, 2015. Income from operations grew by 41.6 per cent

Cipla Q1 net profit zooms over two-fold to Rs 651 cr

Drug major Cipla today reported an over two-fold jump in its consolidated net profit to Rs 650.61 crore for the quarter ended June 30, 2015 mainly on account of robust sales.

Cipla stake

Cipla to launch new respiratory inhaler Synchrobreathe

Will be beneficial for physicians, patients and healthcare providers on managing OBD

Advertisement
Income Tax Calculator, Budget 2019, How to Calculate Income Tax

 

Stock Market

Most Read

Advertisement

Top News

Advertisement

Related Articles